Home Featured Page 93

Featured

Latest

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

Analysis: Patent Applications Provide Hints at Terran Biosciences’ Strategy

PT427 – The Philosophy of Law Enforcement, The Criminalization of Self-Directed...

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment...

MIND CURE ANNOUNCES LNG ENERGY GROUP CREDIT AGREEMENT IN THE AMOUNT...

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Optimi Health Announces Receipt of Purported Termination Notice

Navigating Psychedelics: Vital Tools for Risk Reduction and Integration – Denver

Atman Psychedelic Retreat & Vital Training: Jamaica 1

Kiyumí Psilocybin Retreat & Vital Training: Netherlands

Prasada Transpersonal Breathwork Retreat: Portugal

EDITOR PICKS

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelics & Society

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

Analysis: Patent Applications Provide Hints at Terran Biosciences’ Strategy

PT427 – The Philosophy of Law Enforcement, The Criminalization of Self-Directed...

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment...

MIND CURE ANNOUNCES LNG ENERGY GROUP CREDIT AGREEMENT IN THE AMOUNT...

Small Pharma Reports Fiscal First Quarter 2024 Highlights

Optimi Health Announces Receipt of Purported Termination Notice

Navigating Psychedelics: Vital Tools for Risk Reduction and Integration – Denver

Atman Psychedelic Retreat & Vital Training: Jamaica 1

Kiyumí Psilocybin Retreat & Vital Training: Netherlands

Prasada Transpersonal Breathwork Retreat: Portugal

EDITOR PICKS

Psychedelics & Society

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY